Next Article in Journal
Influence of the Hydrophobicity of Pluronic Micelles Encapsulating Curcumin on the Membrane Permeability and Enhancement of Photoinduced Antibacterial Activity
Next Article in Special Issue
Conjugation of Hypericin to Gold Nanoparticles for Enhancement of Photodynamic Therapy in MCF-7 Breast Cancer Cells
Previous Article in Journal
An Overview of Herbal-Based Antidiabetic Drug Delivery Systems: Focus on Lipid- and Inorganic-Based Nanoformulations
Previous Article in Special Issue
Theranostic Properties of Crystalline Aluminum Phthalocyanine Nanoparticles as a Photosensitizer
 
 
Review
Peer-Review Record

Quantum Dots Mediated Imaging and Phototherapy in Cancer Spheroid Models: State of the Art and Perspectives

Pharmaceutics 2022, 14(10), 2136; https://doi.org/10.3390/pharmaceutics14102136
by Luca Dirheimer 1, Thomas Pons 2, Frédéric Marchal 1 and Lina Bezdetnaya 1,*
Reviewer 1:
Reviewer 2:
Pharmaceutics 2022, 14(10), 2136; https://doi.org/10.3390/pharmaceutics14102136
Submission received: 9 September 2022 / Revised: 3 October 2022 / Accepted: 5 October 2022 / Published: 8 October 2022
(This article belongs to the Special Issue Study of Nanoparticles for Photodynamic Therapy and Imaging)

Round 1

Reviewer 1 Report

Researchers Dirheimer et al. conducted a review of the applications of quantum dots in cancer imaging and therapy, with a particular emphasis on spheroids. The review is quite detailed but I have the following curiosity.

 

1.     The author should add a sentence or two to clarify the distinction between nanoparticles and quantum dots. Please explain how quantum dots are distinct from nanoparticles.

2.     Can 22 nm diameter size come under quantum dots? See Line 283. Does it fall inside the definition that is presented in Line 105 “QDs generally measure between 2 and 10 nm and have a spherical core”? Author, please make the necessary changes.

3.     Additionally, the author should add a heading for the many approaches that can be taken to synthesize/functionalize the QDs.

4.     I think the review does a good job of presenting the tables. On the other hand, some figures associated with the application are anticipated.

5.     The authors started the introduction with a discussion of the application of QDs to spheroids; however, as the discussion progressed, the authors shifted their attention to untargeted and targeted QDs in PDT and PTT, chemotherapy, and its toxicity. The monolayer format was utilized for the majority of the references and descriptions, as opposed to the spheroidal format. During the process of moving on with the document preparation, I got the impression that the authors strayed from the topic. It is possible that the author will decide to rearrange the document or rewrite the abstract/introduction as well as the title. The Abstract, Introduction, and title of the paper are written in a distinct style from the body of the text.

Overall, the manuscript needs major revision before it can be considered for publication in Pharmaceutics.

Comments for author File: Comments.pdf

Author Response

Please, see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report


Comments for author File: Comments.pdf

Author Response

Please, see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The author should provide the reference in figure 4 and figure 5 for the concept. For example, cite the paper which uses those concepts for therapy.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop